Clinical Trials
2 trialsNCT00866138 2019-12-03
Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
AB Science
Phase 2 Completed
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated